Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Investigation of the knowledge and attitudes of patients who are undergoing hemodialysis treatment regarding their arteriovenous fistula.

Ozen N, Tosun N, Cinar FI, Bagcivan G, Yilmaz MI, Askin D, Mut D, Ozen V, Yenicesu M, Zajm E.

J Vasc Access. 2017 Jan 18;18(1):64-68. doi: 10.5301/jva.5000618. Epub 2016 Nov 3.

PMID:
27834457
2.

Relationship between dialysis adequacy and sleep quality in haemodialysis patients.

Tosun N, Kalender N, Cinar FI, Bagcivan G, Yenicesu M, Dikici D, Kaya D.

J Clin Nurs. 2015 Oct;24(19-20):2936-44. doi: 10.1111/jocn.12908. Epub 2015 Jul 27.

PMID:
26215674
3.

Neutrophil to lymphocyte ratio independently predicts cardiovascular events in patients with chronic kidney disease.

Solak Y, Yilmaz MI, Sonmez A, Saglam M, Cakir E, Unal HU, Gok M, Caglar K, Oguz Y, Yenicesu M, Karaman M, Ay SA, Gaipov A, Turk S, Vural A, Carrero JJ.

Clin Exp Nephrol. 2013 Aug;17(4):532-40. doi: 10.1007/s10157-012-0728-x. Epub 2012 Nov 20.

PMID:
23180042
4.

Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients.

Kanbay M, Yilmaz MI, Apetrii M, Saglam M, Yaman H, Unal HU, Gok M, Caglar K, Oguz Y, Yenicesu M, Cetinkaya H, Eyileten T, Acikel C, Vural A, Covic A.

Am J Nephrol. 2012;36(3):228-37. Epub 2012 Aug 30.

PMID:
22948239
5.

Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD.

Carrero JJ, Kyriazis J, Sonmez A, Tzanakis I, Qureshi AR, Stenvinkel P, Saglam M, Stylianou K, Yaman H, Taslipinar A, Vural A, Gok M, Yenicesu M, Daphnis E, Yilmaz MI.

Clin J Am Soc Nephrol. 2012 Feb;7(2):207-15. doi: 10.2215/CJN.06840711. Epub 2011 Dec 22.

6.

Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial.

Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Mallamaci F, Zoccali C.

Am J Kidney Dis. 2012 Feb;59(2):177-85. doi: 10.1053/j.ajkd.2011.11.007. Epub 2011 Dec 2.

PMID:
22137672
7.

The relationship between inflammation, endothelial dysfunction and proteinuria in patients with diabetic nephropathy.

Taslipinar A, Yaman H, Yilmaz MI, Demirbas S, Saglam M, Taslipinar MY, Agilli M, Kurt YG, Sonmez A, Azal O, Bolu E, Yenicesu M, Kutlu M.

Scand J Clin Lab Invest. 2011 Nov;71(7):606-12. doi: 10.3109/00365513.2011.598944. Epub 2011 Aug 24.

PMID:
21864054
8.

Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease.

Yilmaz MI, Sonmez A, Qureshi AR, Saglam M, Stenvinkel P, Yaman H, Eyileten T, Caglar K, Oguz Y, Taslipinar A, Vural A, Gok M, Unal HU, Yenicesu M, Carrero JJ.

Clin J Am Soc Nephrol. 2011 Jul;6(7):1617-25. doi: 10.2215/CJN.10681210. Epub 2011 Jun 23.

9.

Testosterone deficiency is a cause of anaemia and reduced responsiveness to erythropoiesis-stimulating agents in men with chronic kidney disease.

Carrero JJ, Bárány P, Yilmaz MI, Qureshi AR, Sonmez A, Heimbürger O, Ozgurtas T, Yenicesu M, Lindholm B, Stenvinkel P.

Nephrol Dial Transplant. 2012 Feb;27(2):709-15. doi: 10.1093/ndt/gfr288. Epub 2011 May 26.

PMID:
21617198
10.

Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease.

Kanbay M, Yilmaz MI, Sonmez A, Turgut F, Saglam M, Cakir E, Yenicesu M, Covic A, Jalal D, Johnson RJ.

Am J Nephrol. 2011;33(4):298-304. doi: 10.1159/000324847. Epub 2011 Mar 8.

11.

Vascular health, systemic inflammation and progressive reduction in kidney function; clinical determinants and impact on cardiovascular outcomes.

Yilmaz MI, Stenvinkel P, Sonmez A, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Çakar M, Altun B, Yenicesu M, Carrero JJ.

Nephrol Dial Transplant. 2011 Nov;26(11):3537-43. doi: 10.1093/ndt/gfr081. Epub 2011 Mar 4.

PMID:
21378154
12.

Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes.

Yilmaz MI, Sonmez A, Ortiz A, Saglam M, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Çakar M, Egido J, Altun B, Yenicesu M, Blanco-Colio LM, Carrero JJ.

Clin J Am Soc Nephrol. 2011 Apr;6(4):785-92. doi: 10.2215/CJN.09231010. Epub 2011 Feb 17.

13.

Low triiodothyronine alters flow-mediated vasodilatation in advanced nondiabetic kidney disease.

Yilmaz MI, Sonmez A, Karaman M, Ay SA, Saglam M, Yaman H, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Zoccali C.

Am J Nephrol. 2011;33(1):25-32. doi: 10.1159/000322581. Epub 2010 Dec 9.

PMID:
21150192
14.

FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease.

Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Demirkaya E, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Zoccali C.

Kidney Int. 2010 Oct;78(7):679-85. doi: 10.1038/ki.2010.194. Epub 2010 Jul 7.

15.

Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy.

Eyileten T, Sonmez A, Saglam M, Cakir E, Caglar K, Oguz Y, Vural A, Yenicesu M, Yilmaz MI.

Nephrology (Carlton). 2010 Mar;15(2):225-9. doi: 10.1111/j.1440-1797.2009.01173.x.

PMID:
20470283
16.

Irritable bowel syndrome in haemodialysis: Prevalence, link with quality of life and depression.

Afsar B, Elsurer R, Yilmaz MI, Eyileten T, Yenicesu M.

Nephrology (Carlton). 2010 Mar;15(2):197-202. doi: 10.1111/j.1440-1797.2009.01189.x.

PMID:
20470279
17.

Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation.

Yilmaz MI, Carrero JJ, Martín-Ventura JL, Sonmez A, Saglam M, Celik T, Yaman H, Yenicesu M, Eyileten T, Moreno JA, Egido J, Blanco-Colio LM.

Clin J Am Soc Nephrol. 2010 Jul;5(7):1174-81. doi: 10.2215/CJN.01110210. Epub 2010 Apr 29.

18.

Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway?

Yilmaz MI, Sonmez A, Saglam M, Yaman H, Cayci T, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Axelsson J.

Nephrol Dial Transplant. 2010 Oct;25(10):3250-6. doi: 10.1093/ndt/gfq159. Epub 2010 Mar 26.

PMID:
20348148
19.

No regression of renal amyloid mass despite remission of nephrotic syndrome in a patient with TRAPS following etanercept therapy.

Simsek I, Kaya A, Erdem H, Pay S, Yenicesu M, Dinc A.

J Nephrol. 2010 Jan-Feb;23(1):119-23.

PMID:
20091495
20.

Predictors of carotid artery intima-media thickness in chronic kidney disease and kidney transplant patients without overt cardiovascular disease.

Yilmaz MI, Qureshi AR, Carrero JJ, Saglam M, Suliman ME, Caglar K, Eyileten T, Sonmez A, Oguz Y, Vural A, Yenicesu M, Axelsson J.

Am J Nephrol. 2010;31(3):214-21. doi: 10.1159/000272936. Epub 2009 Dec 31.

PMID:
20068285
21.

A case of crescentic IgA nephropathy treated with prednisolone and cyclophosphamide.

Sengul E, Eyileten T, Ozcan A, Yilmaz MI, Yenicesu M.

Hippokratia. 2009 Jul;13(3):172-4.

22.

Diffuse alveolar hemorrhage as an unusual presentation of systemic lupus erythematosus.

Sengul E, Eyıleten T, Ozcan A, Yılmaz MI, Yenıcesu M.

Rheumatol Int. 2011 Aug;31(8):1085-7. doi: 10.1007/s00296-009-1227-6. Epub 2009 Oct 27.

PMID:
19908046
23.

The relationship between hemoglobin levels and endothelial functions in diabetes mellitus.

Sonmez A, Yilmaz MI, Saglam M, Kilic S, Eyileten T, Uckaya G, Caglar K, Oguz Y, Vural A, Yenicesu M, Kutlu M, Kinalp C, Zoccali C.

Clin J Am Soc Nephrol. 2010 Jan;5(1):45-50. doi: 10.2215/CJN.05080709. Epub 2009 Oct 15.

24.

Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease.

Yilmaz MI, Carrero JJ, Ortiz A, Martín-Ventura JL, Sonmez A, Saglam M, Yaman H, Yenicesu M, Egido J, Blanco-Colio LM.

Clin J Am Soc Nephrol. 2009 Nov;4(11):1716-23. doi: 10.2215/CJN.02760409. Epub 2009 Oct 9.

25.

Anti-glomerular basement membrane disease with nephrotic proteinuria.

Sengul E, Eyileten T, Ozcan A, Yilmaz MI, Yenicesu M.

Clin Nephrol. 2009 Aug;72(2):157-9. No abstract available.

PMID:
19640376
26.

Normalization of endothelial dysfunction following renal transplantation is accompanied by a reduction of circulating visfatin/NAMPT. A novel marker of endothelial damage?

Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, Eyileten T, Sonmez A, Oguz Y, Aslan I, Vural A, Yenicesu M, Stenvinkel P, Lindholm B, Axelsson J.

Clin Transplant. 2009 Mar-Apr;23(2):241-8.

PMID:
19402217
27.

Hemoglobin is inversely related to flow-mediated dilatation in chronic kidney disease.

Yilmaz MI, Sonmez A, Saglam M, Gulec M, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Yenicesu M, Zoccali C.

Kidney Int. 2009 Jun;75(12):1316-1321. doi: 10.1038/ki.2009.63. Epub 2009 Mar 4.

28.

Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria.

Yilmaz MI, Axelsson J, Sonmez A, Carrero JJ, Saglam M, Eyileten T, Caglar K, Kirkpantur A, Celik T, Oguz Y, Vural A, Yenicesu M, Lindholm B, Stenvinkel P.

Clin J Am Soc Nephrol. 2009 Mar;4(3):535-41. doi: 10.2215/CJN.04330808. Epub 2009 Feb 11.

29.

The relationship between adiponectin levels and degree of proteinuria in patients with nephrotic and non-nephrotic proteinuria.

Oguz Y, Yilmaz MI, Acikel C, Eyileten T, Caglar K, Oktenli C, Yenicesu M, Vural A.

Ren Fail. 2009;31(1):29-35. doi: 10.1080/08860220802546461.

PMID:
19142807
30.
31.

Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease.

Suliman ME, Yilmaz MI, Carrero JJ, Qureshi AR, Saglam M, Ipcioglu OM, Yenicesu M, Tong M, Heimbürger O, Barany P, Alvestrand A, Lindholm B, Stenvinkel P.

Clin J Am Soc Nephrol. 2008 Jul;3(4):976-85. doi: 10.2215/CJN.03960907. Epub 2008 Apr 16.

32.

Serum fetuin-a concentration and endothelial dysfunction in chronic kidney disease.

Caglar K, Yilmaz MI, Saglam M, Cakir E, Kilic S, Sonmez A, Eyileten T, Yenicesu M, Oguz Y, Tasar M, Vural A, Ikizler TA, Stenvinkel P, Lindholm B.

Nephron Clin Pract. 2008;108(3):c233-40. doi: 10.1159/000120209. Epub 2008 Mar 11.

PMID:
18334823
33.

ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction.

Yilmaz MI, Sonmez A, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, Cakir E, Oguz Y, Vural A, Yenicesu M, Lindholm B, Stenvinkel P, Axelsson J.

J Am Soc Nephrol. 2008 Feb;19(2):388-95. doi: 10.1681/ASN.2007040461. Epub 2008 Jan 16.

34.

Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin.

Yilmaz MI, Saglam M, Qureshi AR, Carrero JJ, Caglar K, Eyileten T, Sonmez A, Cakir E, Oguz Y, Vural A, Yenicesu M, Stenvinkel P, Lindholm B, Axelsson J.

Nephrol Dial Transplant. 2008 May;23(5):1621-7. doi: 10.1093/ndt/gfm828. Epub 2008 Jan 5.

PMID:
18175782
35.

Hyperbaric oxygen treatment augments the efficacy of cilazapril and simvastatin regimens in an experimental nephrotic syndrome model.

Sonmez A, Yilmaz MI, Korkmaz A, Topal T, Caglar K, Kaya A, Eyileten T, Yenicesu M, Oguz Y, Basal S, Ipcioglu OM, Vural A.

Clin Exp Nephrol. 2008 Apr;12(2):110-118. doi: 10.1007/s10157-007-0017-2. Epub 2008 Jan 5.

PMID:
18175058
36.

Short-term treatment with sevelamer increases serum fetuin-a concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients.

Caglar K, Yilmaz MI, Saglam M, Cakir E, Acikel C, Eyileten T, Yenicesu M, Oguz Y, Vural A, Carrero JJ, Axelsson J, Lindholm B, Stenvinkel P.

Clin J Am Soc Nephrol. 2008 Jan;3(1):61-8. Epub 2007 Dec 5.

37.

Idiopathic tubulointerstitial nephritis and uveitis--'TINU syndrome'.

Eyileten T, Dede F, Yenicesu M, Celebi G, Vural A.

Nephrol Dial Transplant. 2008 Feb;23(2):771-2. Epub 2007 Nov 16. No abstract available.

PMID:
18024480
38.

Serum visfatin concentration and endothelial dysfunction in chronic kidney disease.

Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, Eyileten T, Sonmez A, Cakir E, Yenicesu M, Lindholm B, Stenvinkel P, Axelsson J.

Nephrol Dial Transplant. 2008 Mar;23(3):959-65. Epub 2007 Nov 4.

PMID:
17984105
39.

Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan.

Yilmaz MI, Saglam M, Sonmez A, Caglar K, Cakir E, Kurt Y, Eyileten T, Tasar M, Acikel C, Oguz Y, Vural A, Yenicesu M.

Blood Purif. 2007;25(4):327-35. Epub 2007 Aug 20.

PMID:
17709915
40.

Case report: Isospora belli infection in a renal transplant recipent.

Koru O, Araz RE, Yilmaz YA, Ergüven S, Yenicesu M, Pektaş B, Tanyüksel M.

Turkiye Parazitol Derg. 2007;31(2):98-100.

PMID:
17594646
41.

Leukodepletion improves renal function in patients with renal dysfunction undergoing on-pump coronary bypass surgery: a prospective randomized study.

Bolcal C, Akay HT, Bingol H, Doganci S, Yildirim V, Yenicesu M, Demirkilic U, Tatar H.

Thorac Cardiovasc Surg. 2007 Mar;55(2):89-93.

PMID:
17377860
42.

Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome.

Yilmaz MI, Sonmez A, Caglar K, Celik T, Yenicesu M, Eyileten T, Acikel C, Oguz Y, Yavuz I, Vural A.

Nephrology (Carlton). 2007 Apr;12(2):147-53.

PMID:
17371337
43.

Endothelial dysfunction and fetuin A levels before and after kidney transplantation.

Caglar K, Yilmaz MI, Saglam M, Cakir E, Kilic S, Eyileten T, Sonmez A, Oguz Y, Oner K, Ors F, Vural A, Yenicesu M.

Transplantation. 2007 Feb 27;83(4):392-7.

PMID:
17318070
44.

ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease.

Caglar K, Yilmaz MI, Sonmez A, Cakir E, Kaya A, Acikel C, Eyileten T, Yenicesu M, Oguz Y, Bilgi C, Oktenli C, Vural A, Zoccali C.

Kidney Int. 2006 Aug;70(4):781-7. Epub 2006 Jul 5.

45.

Persistent mediastinal and axillary lymph node tuberculosis in a renal transplant patient with successful outcome.

Oguz Y, Yilmaz MI, Eyileten T, Caglar K, Yenicesu M, Kaya A, Tasar M, Saglam M, Doganci L, Gulec B, Oner K, Oktenli C, Vural A.

Transplant Proc. 2006 Jun;38(5):1336-40.

PMID:
16797296
46.

Hyperbaric oxygen treatment augments the efficacy of a losartan regime in an experimental nephrotic syndrome model.

Yilmaz MI, Korkmaz A, Kaya A, Sonmez A, Caglar K, Topal T, Eyileten T, Yenicesu M, Acikel C, Oter S, Yaman H, Aktug H, Oguz Y, Vural A, Ikizler TA.

Nephron Exp Nephrol. 2006;104(1):e15-22. Epub 2006 May 11.

PMID:
16699289
47.

Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation.

Yilmaz MI, Saglam M, Caglar K, Cakir E, Ozgurtas T, Sonmez A, Eyileten T, Yenicesu M, Acikel C, Oguz Y, Ozcan O, Bozlar U, Erbil K, Aslan I, Vural A.

Transplantation. 2005 Dec 27;80(12):1660-6.

PMID:
16378057
48.

Adiponectin level is reduced and inversely correlated with the degree of proteinuria in type 2 diabetic patients.

Yenicesu M, Yilmaz MI, Caglar K, Sonmez A, Eyileten T, Kir T, Acikel C, Bingol N, Oguz Y, Ikizler TA, Vural A.

Clin Nephrol. 2005 Jul;64(1):12-9.

PMID:
16047640
49.

Peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist increases plasma adiponectin levels in type 2 diabetic patients with proteinuria.

Yilmaz MI, Sonmez A, Caglar K, Gok DE, Eyileten T, Yenicesu M, Acikel C, Bingol N, Kilic S, Oguz Y, Vural A.

Endocrine. 2004 Dec;25(3):207-14.

PMID:
15758247
50.

Blockade of the renin-angiotensin system increases plasma adiponectin levels in type-2 diabetic patients with proteinuria.

Yenicesu M, Yilmaz MI, Caglar K, Sonmez A, Eyileten T, Acikel C, Kilic S, Bingol N, Bingol S, Vural A.

Nephron Clin Pract. 2005;99(4):c115-21. Epub 2005 Feb 10.

PMID:
15711099

Supplemental Content

Loading ...
Support Center